ACM
BLUE

Apex Capital Management’s bluebird bio BLUE Stock Holding History

Apex Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$2.48M Buy
4,504
+820
+22% +$504K 0.05% 182
2015
Q4 		$3.06M Buy
3,684
+260
+8% +$260K 0.07% 172
2015
Q3 		$3.79M Buy
+3,424
New +$6.24M 0.09% 163

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Apex Capital Management's BLUE Position: Q1 2016 in Review

Apex Capital Management increased its bluebird bio (BLUE) stake by 22% in Q1 2016, buying an estimated $504K and bringing the position to 4,504 shares worth $2.48M. The position accounts for 0.05% of the portfolio, ranked #182.

Apex Capital Management first reported a position in BLUE in Q3 2015 and has held it in 3 quarters since. The position peaked at $3.79M in Q3 2015. 187 funds tracked by Wall St. Rank hold BLUE as of Q1 2016.

  • Apex Capital Management held 4,504 shares of bluebird bio worth $2.48M as of Q1 2016.
  • Apex Capital Management bought 820 bluebird bio shares in Q1 2016, an estimated $504K.
  • bluebird bio made up 0.05% of Apex Capital Management's portfolio in Q1 2016, its #182 holding.
  • Apex Capital Management first reported a position in bluebird bio in Q3 2015 and has held it in 3 quarters since.
  • Apex Capital Management's bluebird bio position peaked at $3.79M in Q3 2015.
  • 187 funds tracked by Wall St. Rank held bluebird bio as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.